HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on ORIC Pharmaceuticals and raises the price target from $13 to $16.
October 26, 2023 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ORIC Pharmaceuticals' price target has been raised from $13 to $16 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The increase in price target by HC Wainwright & Co. indicates a positive outlook for ORIC Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100